Press releases

Beactica to present pipeline update at NLSDays


Uppsala, Sweden – 21 August 2018

Beactica, the Swedish drug discovery company, today announced that it has been selected for a company presentation at NLSDays 2018 in Stockholm, on 11th September.

Per Källblad, CEO, will deliver an update on Beactica and its pipeline of novel cancer therapeutics during the first Pharmaceuticals Company Presentations session in room 24–25, September 11th at 09:58 am.

Beactica is a specialist drug discovery company with proprietary methodologies for evaluating the interaction of molecules in order to generate novel therapeutics. Beactica has made significant progress in its discovery pipeline over the past 12 months, particularly with the LSD1 programme, which aims to develop a novel class of compounds to treat glioblastoma. This programme is generating interest from investors and pharmaceutical companies on an international level, and has recently received significant funding from both the Swedish Agency for Innovation Systems (VINNOVA) and European Horizon 2020.

Nordic Life Science Days (NLSDays) is the largest Nordic partnering conference that’s dedicated to the life science industry. It attracts leading decision-makers from diverse organisations across the field, from biotech, pharma and medtech to finance, research, policy and regulatory authorities.

Dr Per Källblad (CEO) and Dr Ulf Bremberg (CSO) will be available for partnering meetings during the event, please contact Per to find out more about Beactica.

About Beactica

Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes in areas of unmet medical need, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as a world-leader in fragment-based drug discovery using SPR biosensor technology. For more information on Beactica, please visit www.beactica.com.

Contact

Per Källblad M.Sc. Ph.D.
CEO
per.kallblad@beactica.com
Tel: +46 18 56 08 80